TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00772967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Study: NCT01936337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical administration on psoriatic plaque
Study: NCT02707757
Drug: Erythopoietin stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
Study: NCT01379586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
Study: NCT02171715
Drug: BIBW 2992 MA2
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated immediate release tablet - final formulation
Study: NCT02171715
Drug: BIBW 2992 MA2
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated immediate release tablet - trial formulation II
Study: NCT04370262
Drug: SOC + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care treatment plus IV placebo
Study: NCT00108810
Drug: Transdermal Ketoprofen Patch with CHADD
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 hours patch application for 28 days
Study: NCT00108810
Drug: Placebo transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 hours application for 28 days
Study: NCT04076761
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTD/TPI is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine is the active cytotoxic component of FTD/TPI; its triphosphate form is incorporated into DNA, with such incorporation appearing to result in its anti- tumor effects. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase and, when combined with trifluridine to form FTD/TPI, prevents the rapid degradation of the trifluridine, allowing for the maintenance of adequate plasma levels of the active drug.
Study: NCT00804440
Drug: Ibuprofen Tablets, 800 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04653415
Drug: Tablet
Normalized name: TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The controls group will receive placebo orally - a tablet without any pharmacological properties, intravenously - normal saline solution
Study: NCT04737720
Drug: Recombinant LCAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv infusion
Study: NCT02334969
Drug: Naoxintong Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
Study: NCT02334969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
Study: NCT02612714
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
Study: NCT01048515
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine capsule 6 mg/kg given 1 hour before test
Study: NCT03531957
Drug: ASN002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of ASN002 for 12 weeks
Study: NCT02627950
Drug: Morphinhydrochloricum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg morphine intravenously
Study: NCT00385086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with placebo
Study: NCT03851640
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01399827
Drug: ADHD Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
Study: NCT00501852
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose dry-powder inhaler (SDDPI)
Study: NCT00501852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-dose dry-powder inhaler (SDDPI)
Study: NCT01221545
Drug: AZD1656
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
Study: NCT01221545
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04210713
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg/day
Study: NCT01221298
Drug: ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT00010023
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02762864
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
Study: NCT02903511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring of safety and tolerability
Study: NCT01225068
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
Study: NCT03312855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, intravenous application of Placebo solution
Study: NCT00955110
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15mg or 30mg
Study: NCT00955110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo was a sugar pill.
Study: NCT04066881
Drug: Control PrEP:TDF/FTC once daily (weeks 0-26)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Study: NCT04066881
Drug: Experimental PrEP:TAF/FTC once daily (weeks 0-26)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet of Descovy contains 25mg of tenofovir alfenamide (TAF) and 200mg of emtricitabine (FTC), both of which are nucleot/side analogue HIV-1 reverse transcriptase inhibitors.
Study: NCT01211964
Drug: LEO 22811
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of solution and tablet.
Study: NCT01210768
Drug: Epirubicin+Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
Study: NCT01210768
Drug: liposomal-doxorubicin+Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
Study: NCT05126615
Drug: Auriculotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of a bolus of 5 μ of liquid nitrogen via a cryospray on the auriculotherapy points A4, C18, D9, C9, DIX, H13, G14 and FXVII, chosen according to a neurophysiological reasoning taking into account the surgical intervention performed and innervation of the anatomical region affected by the intervention.
Study: NCT00693212
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing is identical to the MPH arm except that the pills will contain no active medication.
Study: NCT02183467
Drug: BI 1356, low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183467
Drug: BI 1356, high dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01893788
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 to 100 mg daily for 48 weeks
Study: NCT02463591
Drug: Beriplex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beriplex 50 IU/Kg i.v. , single dose.
Study: NCT03524872
Drug: Mouthwashes
Normalized name: MOUTHWASHES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be prescribed mouth-rinse with chlorhexidine 0.12% twice daily starting 3 days prior to surgery and for 2 weeks afterward
Study: NCT00875420
Drug: RAD1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg Oral once a day for 28 days
Study: NCT00875420
Drug: RAD1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Oral once a day for 28 days.
Study: NCT00875420
Drug: RAD1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Oral once a day for 28 days
Study: NCT00875420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral once a day for 28 days
Study: NCT03750136
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose furosemide with hypertonic saline 3x daily
Study: NCT03575130
Drug: Optive eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears (placebo)
Study: NCT00001259
Drug: Estradiol Patches
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal Estradiol, 100mcg/day by skin patch
Study: NCT00001259
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by skin patch
Study: NCT00001259
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given intramuscularly monthly
Study: NCT00001259
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal suppository
Study: NCT04105140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo (24 IU)
Study: NCT03440112
Drug: Clarithromycin (Not used as of 4/2020)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (generic) capsule 250mg each
Study: NCT03440112
Drug: Placebo (Added 4/2020)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal placebo
Study: NCT03199911
Drug: Topical Antibiotic Product
Normalized name: Betadine Antibiotic Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotic ointment will be erythromycin or bacitracin. If the patient cannot obtain either (e.g. lack of availability at the pharmacy), bacitracin polymyxin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
Study: NCT03199911
Drug: Topical Non-Antibiotic Ointment
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral oil/petrolatum-based artificial tear ointment.
Study: NCT01972477
Drug: DLBS1449
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
Study: NCT02484261
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg for age \< 8 years, 20 mg for age 8-\<13 years, 40 mg for ages \>14 years
Study: NCT01401140
Drug: St Thomas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
Study: NCT01401140
Drug: Custodiol
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
Study: NCT03963544
Drug: oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR as per recommendations
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR
Study: NCT03095105
Drug: 200 mg BIA 6-512
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
Study: NCT01962454
Drug: Placebo to match testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
Study: NCT03279237
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: May help shrink tumor before surgery.
Study: NCT00338936
Drug: Valsartan + Hydrochlorothiazide
Normalized name: hydrochlorothiazide / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03125642
Drug: AraC
Normalized name: Carac
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2
Study: NCT03125642
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6
Study: NCT01381523
Drug: Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)
Normalized name: sumatriptan and naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
Study: NCT01381523
Drug: Single-entity oral triptans
Normalized name: Ajuga reptans whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
Study: NCT04727112
Drug: Usual care versus primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT study
Study: NCT00100555
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00215501
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally twice a day for 14 days (dosage will vary)
Study: NCT00120393
Drug: LPV/r +2 NRTIs (Delayed/optional Switch Group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
Study: NCT01219738
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single inhaled dose of placebo from a DPI.
Study: NCT03274700
Drug: Placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
Study: NCT02162810
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
Study: NCT02162810
Drug: placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
Study: NCT05506371
Drug: No interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostocs to confirm the healthy state of the gingiva
Study: NCT00243893
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Study: NCT00243893
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
Study: NCT01954628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT02241018
Drug: calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02718846
Drug: Meniace
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of Meniace tablets were administered 3 times per day after meals
Study: NCT02718846
Drug: Isobide
Approvals — FDA: no, EMA: no, PMDA: no
Description: an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
Study: NCT01853124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
Study: NCT01853124
Drug: Lacidofil
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
Study: NCT00318708
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin 500 mg twice daily (Biaxin)
Study: NCT00318708
Drug: placebo clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo clarithromycin twice daily
Study: NCT01538173
Drug: 250ml HES 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application twice a day 250ml HES 6% for three days postoperatively.
Study: NCT01538173
Drug: 9% NaCl 500ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application twice a day 500ml 9% NaCl for three days postoperatively.
Study: NCT03342443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive placebo with a dosage of one halfpill at 8 am daily for one week (Week 1), then one halfpillat 8 am andone half pill at 5 pm for one week (Week 2), then one pillat 8 am and one half pill at 5 pm for one week (Week 3), then one pill at 8 am and one pill at 5 pm for 21 weeks (Week 4-24), in the absence of unacceptable toxicity or severe deterioration.
Study: NCT00401583
Drug: GW786034 (pazopanib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib will be given as monohydrochloride, 100 and 500 mg tablets.
Study: NCT02884115
Drug: benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00330824
Drug: antibiotic/steroid combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1gtt, 4x/d, 15 days
Study: NCT04544956
Drug: GSK3228836
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3228836 will be available as a clear colorless to slightly yellow solution for injection in 150 mg/milliliters (mL) vial to be administered SC once weekly.
Study: NCT03029403
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
Study: NCT04351152
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
Study: NCT03522662
Drug: GSK1070806
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10mg/kg infusion on Day 0
Study: NCT01197040
Drug: acid mycophenolic (Myfortic)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
Study: NCT03251469
Drug: Normal Saline, 100mg, iv, Singe dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline, 100mg, administered intravenously, preoperatively in single dose
Study: NCT00851110
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
Study: NCT03935646
Drug: Adderall IR 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: At one of the experimental appointments, participants will be administered a stimulant medication. Following a wait period, the participants will complete executive functioning tasks of working memory and sustained attention.